COVID-19 Vaccines and the Pandemic’s Third Year

The world is still grappling with how to stay ahead of a mutating coronavirus. The vaccine focus has now shifted to sustaining longer-term efforts, and developers like Pfizer and Moderna have successfully updated their vaccines to better match circulating omicron variants.

Included in this Trendline:

  • Pfizer, BioNTech data support new Covid booster’s advantage over original vaccine
  • Novavax details trial results for omicron-targeting booster shots
  • Moderna cuts sales forecasts for its COVID-19 vaccine

Request Free!